<DOC>
	<DOCNO>NCT01498016</DOCNO>
	<brief_summary>Intravenous Busulfan ( iv-Bu ) commonly use part preparation regimen allogeneic hematopoietic stem cell transplantation patient acute leukemia . Though pharmacokinetics data available population America , Europe Japan Korea Asia , data Chinese population . It show high Bu concentration associate toxicity veno-occlusion disease low concentration correlate reduced anti-leukemia effect , thus monitor Bu and/or strategy achieve optimal target Bu concentration accept avoid toxicity maintain anti-leukemia effect may overall improve outcome allo-SCT . Thus conduct pharmacokinetic study Chinese population .</brief_summary>
	<brief_title>Pharmacokinetic Study Busulfan Allogeneic Stem Cell Transplantation Adult Patients With Acute Leukemia</brief_title>
	<detailed_description>All patient receive intravenous Busulfan base condition regimen allogeneic stem cell transplantation . Intravenous Busulfan ( iv-Bu ) give 1.6mg/kg twice daily 4 day condition regimen . Blood sample obtain first 7th dose iv Bulsulfan .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>patient acute myeloid lymphoblastic leukemia 1st second remission age 1855 year inform consent contraindication allogeneic transplantation : active infection , allergy FLu/Bu/CTX , liver renal function damage HLA match relate ( 6/6 ) unrelated donor ( least 8/10 ) age le 18 year 56 year HLA mismatch related donor liver function/renal function damage ( 2 X upper normal range ) mental disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>acute leukemia</keyword>
	<keyword>allogeneic stem cell transplantation</keyword>
	<keyword>busulfan</keyword>
</DOC>